Valuation : Stoke Therapeutics, Inc.

Market Cap 2.04B 1.76B 1.65B 1.5B 2.83B 195B 2.84B 19.56B 7.63B 98.44B 7.66B 7.49B 326B P/E 2026 *
-8.71x
P/E 2027 * -8.8x
Enterprise Value 1.84B 1.58B 1.48B 1.35B 2.55B 175B 2.56B 17.6B 6.87B 88.58B 6.89B 6.74B 294B EV / Sales 2026 *
57.3x
EV / Sales 2027 * 40.1x
Free-Float
96.31%
Yield 2026 *
-
Yield 2027 * -
1 day-2.98%
1 week-2.07%
Current month+9.56%
1 month+7.59%
3 months+0.03%
6 months-13.16%
Current year-0.38%
1 week 31.16
Extreme 31.16
33.94
1 month 28.19
Extreme 28.19
33.94
Current year 25.21
Extreme 25.21
40.22
1 year 18.8
Extreme 18.8
40.22
3 years 3.35
Extreme 3.35
40.22
5 years 3.35
Extreme 3.35
40.22
10 years 3.35
Extreme 3.35
71.58
Manager TitleAgeSince
Chief Executive Officer 60 19/03/2025
Chief Tech/Sci/R&D Officer 54 01/06/2014
Director of Finance/CFO 49 07/05/2024
Director TitleAgeSince
Chairman 65 01/07/2015
Director/Board Member 67 01/06/2014
Director/Board Member 72 01/09/2015
Date Insider Type Main position Quantity % Market Cap.
18/08/26 Sell

Chief Technology Officer

-4,767 0.0081%
18/08/26 Sell

Director

-12,567 0.0212%
18/08/26 Sell

General Counsel

-2,861 0.0048%
Change 5-day change 1-year change 3-year change Capi.($)
-2.98%-2.07%+59.94%+441.44% 2.04B
-0.78%-1.42%+2.49%+22.78% 50.47B
-6.00%-0.75%+442.41%+544.39% 44.56B
-0.24%+0.74%+38.69%+18.02% 43.08B
-1.55%-2.07%+23.08%+81.47% 41.7B
-0.31%-0.83%+16.15%+51.42% 33.21B
-1.79%-3.24%+27.00%+129.56% 16.77B
-0.58%-2.12% - - 16.28B
-0.88%-0.66%+11.60%+27.75% 14.58B
-1.66%-1.25%+78.59%+46.66% 13.92B
Average -1.68%-1.16%+77.77%+151.50% 27.66B
Weighted average by Cap. -1.71%-1.07%+95.43%+136.04%

Financials

2026 *2027 *
Net sales 32.02M 27.6M 25.87M 23.62M 44.49M 3.06B 44.64M 307M 120M 1.55B 120M 118M 5.12B 44.83M 38.63M 36.22M 33.06M 62.28M 4.28B 62.48M 430M 168M 2.16B 168M 165M 7.17B
Net income -241M -207M -194M -177M -334M -23B -335M -2.31B -900M -11.61B -904M -884M -38.5B -261M -225M -211M -193M -363M -24.97B -364M -2.5B -977M -12.6B -981M -960M -41.79B
Net Debt -204M -176M -165M -151M -284M -19.52B -285M -1.96B -764M -9.85B -767M -750M -32.67B -242M -209M -196M -179M -336M -23.14B -337M -2.32B -905M -11.68B -909M -889M -38.72B
Logo Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, zorevunersen (STK-001), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The Company is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.
Employees
170
Date Price Change Volume
28/08/26 $31.62 -2.98% 754,095
27/08/26 $32.59 -1.51% 939,339
26/08/26 $33.09 -1.11% 1,155,276
25/08/26 $33.46 +3.53% 728,630
24/08/26 $32.32 +0.09% 562,290
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
31.62USD
Average target price
46.46USD
Spread / Average Target
+46.94%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. STOK Stock